In recent years, with the deepening of research on the role of PD-L1 in tumor immune microenvironment and the introduction of PD-1/PD-L1 axis inhibitors, the immunotherapy of a variety of malignant tumors has undergone fundamental changes, including liver cancer. This evidence concerns the gene CD274 and cancer.